| Vifor (International) Inc. - Flucelvax, Injektionssuspension in einer Fertigspritze | | 70144 | | 01 | | Flucelvax | | Injektionssuspension in einer Fertigspritze | | J07BB02 | | Influenza, gereinigtes Antigen | | 29.04.2026 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Wisconsin/67/2022 (H1N1)-like: derived from A/Georgia/12/2022 CVR-167) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Massachusetts/18/2022 (H3N2)-like: derived from A/Sydney/1304/2022) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant from B/Singapore/WUH4618/2021 (Victoria lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.74 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum. | | Packungsbestandteile | | Injektionssuspension in einer Fertigspritze | | | | | | Principe actif | Concentr. |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus Stamm A/wisconsin/67/2022 (H1N1)-Like: Derived from A/georgia/12/2022 Cvr-167) | 15µg / 0.5ml | | Haemagglutininum Influenzae a (H3N2) (Virus Stamm A/massachusetts/18/2022 (H3N2)-Like: Derived from A/sydney/1304/2022) | 15µg / 0.5ml | | Haemagglutininum Influenzae b (Virus Stamm B/austria/1359417/2021-Like: Reassortant from B/singapore/wuh4618/2021 (Victoria Lineage)) | 15µg / 0.5ml |
| | | | Agents auxilliaires |
|---|
| Kalii Chloridum | | Potassium Dihydrogenophosphate | | Magnesium Chloride Hexahydrate | | Sodium Chlorure | | Sodium Dihydrogenophosphate Dihydrate |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | | | | B | | Non | | 002 | 10 | | | B | | Non | | 003 | | | | B | | Non | | 004 | 10 | | | B | | Non |
|
|
